Walleye Capital
TRDA icon

Walleye Capital’s Entrada Therapeutics TRDA Stock Holding History

Walleye Capital’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-13,534
Closed -$139K – 4992
2025
Q4 		$139K Sell
13,534
-83,147
-86% -$701K ﹤0.01% 3725
2025
Q3 		$561K Buy
96,681
+79,272
+455% +$464K ﹤0.01% 2520
2025
Q2 		$117K Buy
+17,409
New +$140K ﹤0.01% 3701
2024
Q3 		– Sell
-13,323
Closed -$190K – 5877
2024
Q2 		$190K Buy
+13,323
New +$189K ﹤0.01% 4336
2022
Q2 		– Sell
-44,652
Closed -$419K – 2724
2022
Q1 		$419K Buy
+44,652
New +$479K 0.01% 1107

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
MC
Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
SG
StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Walleye Capital's TRDA Position: Q1 2026 in Review

Walleye Capital sold out of Entrada Therapeutics (TRDA) in Q1 2026, closing a stake of 13,534 shares — an estimated $139K sold.

Walleye Capital first reported a position in TRDA in Q1 2022 and held it in 5 quarters. The position peaked at $561K in Q3 2025. 120 funds tracked by Wall St. Rank hold TRDA as of Q1 2026.

  • Walleye Capital reported no remaining Entrada Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Walleye Capital sold 13,534 Entrada Therapeutics shares in Q1 2026, an estimated $139K.
  • Walleye Capital first reported a position in Entrada Therapeutics in Q1 2022 and held it in 5 quarters.
  • Walleye Capital's Entrada Therapeutics position peaked at $561K in Q3 2025.
  • 120 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.